Balyasny Asset Management
ENTA icon

Balyasny Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Balyasny Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,064
Closed -$470K – 2590
2023
Q3 		$470K Buy
+42,064
New +$677K ﹤0.01% 1776
2019
Q3 		– Sell
-11,013
Closed -$929K – 1282
2019
Q2 		$929K Buy
11,013
+1,210
+12% +$109K 0.01% 1097
2019
Q1 		$936K Buy
+9,803
New +$879K 0.01% 1043
2015
Q2 		– Sell
-148,610
Closed -$4.55M – 1194
2015
Q1 		$4.55M Buy
+148,610
New +$5.78M 0.04% 488

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's ENTA Position: Q4 2023 in Review

Balyasny Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 42,064 shares — an estimated $470K sold.

Balyasny Asset Management first reported a position in ENTA in Q1 2015 and held it in 4 quarters. The position peaked at $4.55M in Q1 2015. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Balyasny Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 42,064 Enanta Pharmaceuticals shares in Q4 2023, an estimated $470K.
  • Balyasny Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Balyasny Asset Management's Enanta Pharmaceuticals position peaked at $4.55M in Q1 2015.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.